An Open Label Observational Study of Safety and Efficacy of a Pharmaceutical grade Cannabis Medicine (MediCabilis™-CBD extract Oil) in Patients undergoing Medicinal Cannabis Therapy for Different Indications

Not Applicable

Active, not recruiting

• Conditions: Any approved condition for which MediCabilis has been prescribed for through either Special Access Scheme- Cat B or by an authorised prescriber; Chronic pain; Seizure management/Epilepsy; Post-traumatic stress disorder; Neuropathic pain; Anxiety; Parkinson's disease/Tremor; Dementia; Multiple sclerosis; Insomnia

• Registration Number: ACTRN12620000741987
• Lead Sponsor: Bod Australia

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2020-07-16
• Last Update Posted: 6 December 2021

Recruitment & Eligibility

• Status: Active, not recruiting
• Sex: All
• Target Recruitment: 479

Inclusion Criteria

Participants will be any patient who has been prescribed MediCabilis through the Special Access Scheme B or by an authorised prescriber.
Participants may be taking MediCabilis in any dose, form, duration and free
quency, and for any condition.
Patients of any gender who is equal or greater than 18 years may participate.
Prospective patients that understand the informed consent process and to give informed consent to participate in the study.
Diagnosis of their condition/disease confirmed by patient’s GP or specialist.

Prospective participants agree to abstain from using illicit cannabis products for the duration of their participation in the study.

Exclusion Criteria

Any severe cognitive, intellectual disability, medical or psychiatric condition that impairs the participant’s ability to provide informed consent.
Patients who are using illicit forms of cannabis.

Study & Design

• Study Type: Observational
• Study Design: Not specified